Market Place
Sourcing Support
Biosight Launches a Phase 1/2 Trial of Aspacytarabine with Venetoclax
22 Nov 2022 //
PRNEWSWIRE
Biosight Granted ODD from FDA for Aspacytarabine for Myelodysplastic Syndromes
01 Aug 2022 //
PRNEWSWIRE
Biosight Shows Final Primary Endpoint Data from Phase 2b Study of BST-236 in AML
06 Jan 2022 //
GLOBENEWSWIRE
Biosight Initiates Phase 2 Clinical Trial of Aspacytarabine for MDS and AML
12 Nov 2021 //
GLOBENEWSWIRE
Biosight Announces Initiation of Phase 2 Clinical Trial of Aspacytarabine
16 Aug 2021 //
GLOBENEWSWIRE
Advaxis and Biosight Announce Entry into Definitive Merger Agreement
06 Jul 2021 //
GLOBENEWSWIRE
Biosight to Present Updated Clinical Data from Ongoing Ph 2b Study of (BST-236)
05 Nov 2020 //
GLOBENEWSWIRE
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.